20 articles
A systematic review of 13 studies finds semaglutide and liraglutide meaningfully cut BMI and improve blood sugar in children and adolescents.
A new review argues that combining GLP-1 receptor agonists with structured exercise and dietary support preserves muscle and delivers lasting fat loss.
A Cochrane review of 37 RCTs finds obesity drugs modestly reduce weight in adolescents, but evidence quality is low and long-term data are absent.
A new review maps how tirzepatide's dual GIP/GLP-1 action reshapes metabolism across the pancreas, liver, gut, heart, kidneys, and brain.
Semaglutide and liraglutide show promise for dry eye and corneal repair, but may cause periocular volume loss that affects blinking and tear distribution.
A major review repositions type 2 diabetes as a proteinopathy, with amylin aggregation bridging metabolic decline and neurodegeneration.
A new framework reveals how lactate and β-hydroxybutyrate team up across organs to regulate metabolism, mitochondria, and disease.
Longevity experts endorse short CGM trials for non-diabetics, but RCT evidence remains thin. Here's what the data actually shows.
Dexcom G7 tops expert picks for metabolic biohacking, but evidence for non-diabetics remains mixed. Here's what the data says.
Expert reviews compare top CGMs for longevity use, but evidence for healthy adults remains limited. Here's what you need to know.
Top longevity doctors endorse CGMs for healthy adults, but evidence is mixed. Here's what the 2026 device reviews reveal.
Continuous glucose monitors are popular in biohacking circles, but direct evidence linking CGM use to extended lifespan remains thin.
Longevity experts endorse CGMs for metabolic optimization, but RCT evidence in non-diabetics is still thin.
Expert reviews of top CGM platforms reveal genuine metabolic insights — but no proof they extend lifespan in healthy adults.
A head-to-head review of 10 CGM devices for healthy adults, weighing real-world accuracy data against limited longevity evidence.
Six leading CGM platforms compared on accuracy, evidence quality, and longevity claims — most fall short of the hype.
A new framework redefines age-related insulin resistance as a systemic collapse of metabolic resilience spanning muscle, fat, brain, and more.
Aging adipose tissue loses its ability to generate new fat cells, driving insulin resistance. New review maps the molecular culprits and best treatment options.
A Cochrane meta-analysis of 11 RCTs finds very low-certainty evidence that liver support systems neither reduce mortality nor improve key outcomes in ALF.
A new review reframes magnesium as a master regulator of mitochondrial energy, metabolic disease, and biological aging.
